New Patents Issued Across Multiple Geographies in US, China, Hong Kong and Australia

BOSTON, MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – December, 2017) BioAegis Therapeutics announces that during 2018 its patent portfolio expanded globally in multiple indications. The newly issued patents extend coverage in infection, inflammatory disease, and neurological disease in the United States, China, Honk Kong and Australia. The plasma gelsolin portfolio now includes 30 issued patents and many pending applications.